ClinicalTrials.gg
CompletedNCT04830345Updated Apr 4, 2022

Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

A Phase 3 interventional study of ATGC-100 100U and Botox 100U in Glabellar Frown Lines, sponsored by EuBiologics Co.,Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-04.

Sponsored by EuBiologics Co.,Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2020, registered Mar 2021).
Phase
Phase 3
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.

02

Conditions studied

  • Glabellar Frown Lines
03

In context

Lead sponsor

EuBiologics Co.,Ltd is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female aged 19 to 65 years old
  2. Participants with Facial Wrinkle Scale (FWS) score of > 2 at maximum frown at screening
  3. Participants willing to follow the study procedures and schedules
  4. Participants willing to give written to participate in the trial

Exclusion criteria

Exclusion Criteria:

  1. Participants with severe glabellar lines that cannot be improved physical method
  2. Pregnant, lactating women or women of childbearing age not using a reliable method of
  3. Participants with known to any component of the study drug
  4. Participant who has skin disorder including infection and scar on injection site
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
290 participants (actual)

Study arms

  • Experimental
    ATGC-100 100U

    ATGC-100 will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0

    Biological: ATGC-100 100U

  • Active comparator
    Botox 100U

    Botox inj. will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0

    Biological: Botox 100U

Interventions

  • BiologicalATGC-100 100U

    Clostridium botulinum toxin type A

  • BiologicalBotox 100U

    Clostridium botulinum toxin type A

06

What researchers measure

Primary outcomes

  1. Proportion of patients with improvement of glabellar lines at maximum frown

    Improvement rate of glabellar lines at maximum frown with Physician's Facial wrinkle scale (FWS)

    Time frame: 4 weeks post injection compared to baseline

07

Study locations

1 site
  • Nowon Eulji University Hospital
    Seoul, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04830345
Lead sponsor
EuBiologics Co.,Ltd
Responsible party
Sponsor
First posted
Apr 5, 2021
Start date
Jun 29, 2020
Primary completion
Sep 1, 2021
Completion
Oct 1, 2021
Last update
Apr 4, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion